Anthony Lapointe - SciClone Pharmaceuticals Independent Director
Director
Mr. Gregg A. Lapointe, CPA, is an Independent Director of SciClone Pharmaceuticals, Inc., since March 2009. Mr. Lapointe has served as a Director since March 2009. Mr. Lapointe is currently the Chief Executive Officer of Cerium Pharmaceuticals, Inc., a specialty pharmaceutical company. From April 2008 to February 2012, Mr. Lapointe served as Chief Executive Officer of SigmaTau Pharmaceuticals, Inc., a pharmaceutical company focused on rare disorders and the U.S. whollyowned subsidiary of SigmaTau Finanziaria S.p.A. He served as Chief Operating Officer of SigmaTau Pharmaceuticals, Inc. from December 2003 to March 2008 since 2009.
| Age | 56 |
| Tenure | 15 years |
| Professional Marks | MBA |
| Phone | 650 358-3456 |
| Web | www.sciclone.com |
SciClone Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.16 % which means that it generated a profit of $0.16 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.19 %, meaning that it created $0.19 on every $100 dollars invested by stockholders. SciClone Pharmaceuticals' management efficiency ratios could be used to measure how well SciClone Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 2.73 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. SciClone Pharmaceuticals has a current ratio of 8.19, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist SciClone Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, SciClone Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like SciClone Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for SciClone to invest in growth at high rates of return. When we think about SciClone Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| William Lacey | Parker Hannifin | 55 | |
| Dean Foate | RBC Bearings Incorporated | 61 | |
| Nestor Angulo | Cementos Pacasmayo SAA | N/A | |
| Hugo Castillo | Cementos Pacasmayo SAA | 62 | |
| Anthony Soave | Titan International | 80 | |
| KlausPeter Mueller | Parker Hannifin | 74 | |
| Bradley Rollins | Usio Inc | 46 | |
| Christopher Doerr | RBC Bearings Incorporated | 70 | |
| Linda Harty | Parker Hannifin | 60 | |
| Carlos Ramos | Cementos Pacasmayo SAA | 51 | |
| Joaquin Gubbins | Cementos Pacasmayo SAA | N/A | |
| Gary Cowger | Titan International | 73 | |
| Kevin Lobo | Parker Hannifin | 55 | |
| Blaise Bender | Usio Inc | 61 | |
| Michael Hilton | RBC Bearings Incorporated | 65 | |
| Albert Febbo | Titan International | 78 | |
| James Verrier | Parker Hannifin | 57 | |
| Jane Warner | RBC Bearings Incorporated | 72 | |
| Mark Petrarca | Topbuild Corp | 57 | |
| Margaret Whelan | Topbuild Corp | 45 | |
| Dennis Archer | Topbuild Corp | 75 | |
Management Performance
| Return On Equity | 0.19 | |||
| Return On Asset | 0.16 |
SciClone Pharmaceuticals Leadership Team
Elected by the shareholders, the SciClone Pharmaceuticals' board of directors comprises two types of representatives: SciClone Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SciClone. The board's role is to monitor SciClone Pharmaceuticals' management team and ensure that shareholders' interests are well served. SciClone Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SciClone Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charles Meng, VP of Compliance and General Counsel | ||
| Richard Hawkins, Independent Director | ||
| Gregg Lapointe, Independent Director | ||
| Hong Zhao, CEO of China Operations | ||
| Wilson Cheung, CFO, Sr. VP of Fin. and Secretary | ||
| Nancy Chang, Director | ||
| Anthony Lapointe, Independent Director | ||
| Lan Xie, VP of Fin. and CFO of China Operations | ||
| Raymond Low, Vice President - Finance, Controller | ||
| Robert King, Senior Vice President - Product Development and Supply Chain | ||
| Simon Li, Independent Director | ||
| Jon Saxe, Independent Chairman of the Board | ||
| Friedhelm Blobel, CEO and President Executive Director and Member of Bus. Devel. Committee |
SciClone Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SciClone Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.19 | |||
| Return On Asset | 0.16 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 25.82 % | |||
| Current Valuation | 422 M | |||
| Shares Outstanding | 52.19 M | |||
| Shares Owned By Insiders | 10.03 % | |||
| Shares Owned By Institutions | 79.96 % | |||
| Number Of Shares Shorted | 1.21 M | |||
| Price To Earning | 13.75 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in SciClone Stock
If you are still planning to invest in SciClone Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the SciClone Pharmaceuticals' history and understand the potential risks before investing.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Stocks Directory Find actively traded stocks across global markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |